Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer

Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer Move reflects increasing investment in AI as driving force for innovation and productivity. Company will host Innovation Summit in December focused on AI in R&D. WASHINGTON, June 5, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR), a global science and technology innovator,... Read more

Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis

Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics. This approach could potentially be adapted for diagnosis of other... Read more

Danaher to Present at Bank of America Securities Healthcare Conference

WASHINGTON, May 7, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Tuesday, May 14, 2024 at 10:40 a.m. PT. The event will be simultaneously webcast on www.danaher.com. ABOUT DANAHERDanaher... Read more

Danaher Reports First Quarter 2024 Results

WASHINGTON, April 23, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the quarter ended March 29, 2024.  All results in this release reflect only continuing operations unless otherwise noted. Key First Quarter 2024 Results Net earnings were $1.1 billion, or $1.45 per diluted common share and non-GAAP adjusted diluted net... Read more

Danaher Schedules First Quarter 2024 Earnings Conference Call

WASHINGTON, March 21, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The... Read more

Danaher to Present at TD Cowen Health Care Conference

WASHINGTON, Feb. 27, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Tuesday, March 5, 2024 at 11:10 a.m. ET. The event will be simultaneously webcast on www.danaher.com. ABOUT DANAHERDanaher is a leading global... Read more

Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets

Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets WASHINGTON, Feb. 22, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with the Science Based Targets initiative (SBTi), including a long-term target to reach net-zero value chain emissions... Read more

Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development

Danaher Launches Collaboration with Cincinnati Children’s Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development,... Read more

Danaher Reports Fourth Quarter and Full Year 2023 Results

WASHINGTON, Jan. 30, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the fourth quarter and full year 2023.  All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2023 Results Net earnings were $1.1 billion, or $1.50 per diluted common share and non-GAAP adjusted diluted... Read more

Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution

Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses Innovative model... Read more